A Warburg Pincus-led investor group has agreed to acquire a controlling stake in Pantherx Rare, a US-based pharmacy specializing in rare disease treatments. The sellers were Nautic Partners, General Atlantic and The Vistria Group, who have owned the company since previous investment rounds.

Nautic Partners and Pantherx management will remain significant shareholders following the transaction, ensuring continuity in operations and strategy. Bansi Nagji serves as CEO of Pantherx and will continue to lead the company's growth trajectory.

Pantherx was founded in a garage in Pittsburgh in 2011 and has since grown into a prominent specialty pharmacy platform serving patients with complex chronic conditions. The acquisition reflects continued private equity interest in the specialty pharmacy sector, particularly in rare and orphan disease markets. No financial terms were disclosed for the transaction, which is subject to customary closing conditions and regulatory approvals.